Substituted pteridine compounds and pharmaceutical compositions containing the same

Claim 2

A parenterally administrable pharmaceutical composition for inducing diuresis, said composition comprising a pharmaceutically acceptable carrier for parenteral administration and a diuretically-effective amount of a compound of the formula ##STR12## wherein R is hydrogen or a pharmaceutically acceptable cation.

Claim 3

A composition as in claim 1 wherein said compound is 2,4,7-triamino-6-(p-hydroxyphenyl)-pteridine.

Claim 6

A compound of the formula ##STR14## wherein R' is ##STR15## wherein m is 0, 1, 2, or 3, R 1 is hydrogen, methyl, or ethyl, R 2 is hydrogen, --OH, or alkyl having 1 to 4 carbon atoms, Q is oxygen, sulfur, or --NR 3 , where R 3 ═R 1 , or Q together with R 1 , forms an ammonium ion --N(R 1 ) 3 + Z - , where Z is a pharmaceutically acceptable anion, or Q, together with R 1 , is morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl; or ##STR16## wherein n is 0, 1, 2, 3, or 4 and Y is --OH or a pharmaceutically acceptable salt thereof, or --NR 4 R 5 , wherein R 4 and R 5 are the same or different and are hydrogen or straight-chain or branched alkyl having 1 to 4 carbon atoms, or --(O) r --R 6 , wherein r is 0 or 1 and R 6 is alkyl having 1 to 6 carbon atoms, or --(CH 2 ) q --R 7 wherein q is 0, 1, or 2 and R 7 is morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl bound by a carbon atom thereof or, when q is not 0, R 7 can also be --OH, or ##STR17## wherein v, w, and z are the same or different and are 0, 1, or 2 and R 8 is hydrogen or --OH; or ##STR18## wherein s is 0, 1, 2 or 3; or ##STR19## wherein M is hydrogen, a pharmaceutically acceptable cation, chloro-substituted alkyl having 1 to 3 carbon atoms, or --CH 2 --O--Ar, wherein Ar is phenyl or chloro-substituted phenyl.

Claim 7

A compound of the formula ##STR14## wherein R' is ##STR15## wherein m is 0, 1, 2, or 3, R 1 is hydrogen, methyl, or ethyl, R 2 is hydrogen, --OH, or alkyl having 1 to 4 carbon atoms, Q is oxygen, sulfur, or --NR 3 , where R 3 ═R 1 , or Q together with R 1 , forms an ammonium ion --N(R 1 ) 3 + Z - , where Z is a pharmaceutically acceptable anion, or Q, together with R 1 , is morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl; or ##STR16## wherein n is 0, 1, 2, 3, or 4 and Y is --OH or a pharmaceutically acceptable salt thereof, or --NR 4 R 5 , wherein R 4 and R 5 are the same or different and are hydrogen or straight-chain or branched alkyl having 1 to 4 carbon atoms, or --(O) r --R 6 , wherein r is 0 or 1 and R 6 is alkyl having 1 to 6 carbon atoms, or --(CH 2 ) q --R 7 wherein q is 0, 1, or 2 and R 7 is morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl bound by a carbon atom thereof or, when q is not 0, R 7 can also be --OH, or ##STR17## wherein v, w, and z are the same or different and are 0, 1, or 2 and R 8 is hydrogen or --OH; or ##STR18## wherein s is 0, 1, 2 or 3; or ##STR19## wherein M is hydrogen, a pharmaceutically acceptable cation, chloro-substituted alkyl having 1 to 3 carbon atoms, or --CH 2 --O--Ar, wherein Ar is phenyl or chloro-substituted phenyl.

Claim 8

A compound as in claim 4 which is 2,4,7-triamino-6-(p-acetoxyphenyl)-pteridine.

Claim 9

A compound as in claim 4 which is 2,4,7-triamino-6-(p-succinoylphenyl)-pteridine.

Claim 10

A compound as in claim 4 which is 2,4,7-triamino-6-(adipinoylphenyl)-pteridine.

Claim 11

A compound as in claim 4 which is 2,4,7-triamino-6-(p-2-hydroxyethoxyphenyl)-pteridine.

Claim 12

A compound as in claim 4 which is 2,4,7-triamino-6-(p-2,3-dihydroxypropoxy-phenyl)-pteridine.

Claim 13

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically-effective amount of a compound as in claim 4.

Claim 14

A composition as in claim 10 wherein said compound is 2,4,7-triamino-6-(p-acetoxyphenyl)-pteridine.

Claim 15

The method of inducing diuresis in a patient which comprises orally or parenterally administering to said patient a diuretically-effective amount of a compound as in claim 4.